“Fund planning, reporting and flows, needs estimation and access to innovative drugs. And again: theaccess to therapies, regional health planning, financing of high-cost technologiesor. Our goal is to make those who work in the world of health aware of the path we have started and which is called Synthesis , an initiative born during the pandemic, which aims to question itself on what are the potential distortions of the system and to develop hypotheses of solution together with the actors-decision makers. We did this starting from the Innovative Medicines Fund theme, involving the heads of the regional drug policies of Campania, Emilia Romagna, Liguria, Lazio, Lombardy and Tuscany. With them we questioned the limits and distortions and we arrived at define a series of recommendations that would lead to an improvement and an efficiency of the system and, at the same time, to solicit access to therapies by patients. The hope is that other Regions will follow us too “.
Like this Davide CafieroCEO of Helaglobe, speaking in the afternoon at the webinar-round table ‘Fund for Innovative Medicines and Fund for Rare Diseases‘, promoted and organized by Helaglobe with the non-conditioning contribution of Csl Behring, Roche, Novartis, Daiichi-Sankyo, Pierre Fabre and Servier.
Through the involvement of the other players in the health system that are relevant from time to time with respect to the problem in question – it emerged from the meeting – the analysis that will lead to the definition of the requests for change and recommendations is developed. These elements, always with the methodological support of Synthesis, are transferred to the central institutions (Ministry of Health and Aifa) through position documents that summarize the evidence found and propose possible practical solutions that can be applied.
“Inhomogeneity of regional processes and procedures such as access to therapies, the relationship with regional contracting stations, regional health planning, the financing of high-cost technologies, find in Synthesis a common forum for comparison and analysis”, adds Cafiero . The goal is “identify the obstacles that create potential limitations to access to care for people with pathologies and remove them or at least mitigate them, while generating an efficiency of regional management processes. The transversal analysis of the junctions that generate potential limitations to access to therapies offers the possibility of identifying improvement paths in taking charge and care, including the voice of people with pathology “, concludes the CEO.